Clene Inc. CLNN Archives - Page 4 of 10

TuesdaySep 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership

The company is seeking an accelerated approval regulatory pathway for CNM-Au8® for ALS. The FDA agreed to an in-person meeting to reevaluate Clene’s submission. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering hope for patients with neurodegenerative conditions. The FDA meeting will be held before the end of November and will be attended by top FDA officials and key opinion leaders in ALS, biostatistics and biomarkers. Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative…

WednesdaySep 11, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference

The H.C. Wainwright 26th Annual Global Investment Conference is being held on-line and in person, Sept. 9-11. Clene management will give a virtual presentation of the company’s most recent achievements and results and will hold one-on-one investor meetings. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering new hope for patients with neurodegenerative conditions. The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to…

FridaySep 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

With a focus on improving mitochondrial health, CNM-Au8® stands out among other therapies by targeting the nicotinamide adenine dinucleotide pathway to restore and protect neurological function. Nearly 2 million Americans are affected by amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) or Parkinson’s disease. The global therapeutics markets for neurogenerative diseases are projected to grow substantially, driven by the growing prevalence of these conditions, rising geriatric population and the emergence of new therapies. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal…

TuesdaySep 03, 2024 11:15 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company today announced that its management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST. To view the webcast of the presentation, visit https://ibn.fm/6ncBJ To view the full press release, visit https://ibn.fm/Qkp6L About Clene Inc. Clene…

FridayAug 30, 2024 2:38 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions,” a recent article reads. “Clene has conducted extensive…

WednesdayAug 28, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients In MS, CNM-Au8 can work in conjunction with…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

MondayAug 12, 2024 10:30 am

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8 The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative…

TuesdayAug 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”) CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform.…

FridayJul 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast

Clene's mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions The company’s uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting…

Site Search

Company Search

Tag: Clene Inc. CLNN